Celltrion Wins Korean Phase 1 IND Approval for CT-P68, Targeting 7.7 Trillion Won Market
Celltrion won Korean Phase 1 IND approval for CT-P68, a biosimilar of Johnson & Johnson's Tremfya, targeting a 7.73 trillion won autoimmune treatment market, with trials in 258 adults.
Read the full articleYou might also wanna read
μ νΈλ¦¬μ¨, μκ°λ©΄μ λ°μ΄μ€μλ°λ¬ βCT-P68β κ΅λ΄ μμ 1μ μΉμΈ
μ νΈλ¦¬μ¨μ΄ μκ°λ©΄μμ§ν μΉλ£μ βνΈλ νΌμ΄(μ±λΆλͺ ꡬμ μΏ λ§)β λ°μ΄μ€μλ°λ¬ κ°λ°μ μ°©μνλ€. μ νΈλ¦¬μ¨μ μνμμ½νμμ μ²λ‘λΆν° νΈλ νΌμ΄ λ°μ΄μ€μλ°λ¬ βCT-P68βμ μμ 1μ μνκ³ν(IND)μ μΉμΈλ°μλ€κ³ 15μΌ λ°νλ€. νμ¬λ 건κ°ν μ±μΈ 258λͺ μ
μ νΈλ¦¬μ¨, νΈλ νΌμ΄ λ°μ΄μ€μλ°λ¬ 'CT-P68' μμ 1μ μΉμΈ
μ νΈλ¦¬μ¨μ μνμμ½νμμ μ²λ‘λΆν° 'νΈλ νΌμ΄(μ±λΆλͺ ꡬμ μΏ λ§)' λ°μ΄μ€μλ°λ¬μΈ 'CT-P68'μ μμ 1μ μνκ³ν(IND) μΉμΈμ νλνλ€κ³ 15μΌ λ°νλ€. μ΄λ² μΉμΈμ λ°λΌ νμ¬λ 건κ°ν μ±μΈ 258λͺ μ λμμΌλ‘ μμ μ μ°¨μ μ¦μ λμ νλ©°, μ€λ¦¬μ§λ
Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers
Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in Relapsed/Refractory Multiple Myeloma Publication Supports Continu
Immuneel, Tata Memorial Centre partner to advance cell and gene therapy research
Among the first projects identified under the partnership is a Phase 2 extension study evaluating the safety and efficacy of IMN-003A cell t
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, an
China approves world's first CAR-T cell therapy for solid tumors: CARsgen's satri-cel for advanced gastric cancer
The gastric cancer treatment proves engineered cellular therapies can treat solid tumors.
insideprecisionmedicine.comΒ·21d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.